omeprazole has been researched along with Melanoma in 3 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
Excerpt | Relevance | Reference |
---|---|---|
" This phase I/II study in patients with advanced melanoma evaluated the potential effect of sorafenib on the pharmacokinetics of midazolam, omeprazole, and dextromethorphan, specific substrates of CYP3A4, CYP2C19, and CYP2D6, respectively." | 9.15 | Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ( Flaherty, KT; Frye, RF; Lathia, C; O'Dwyer, PJ; Redlinger, M; Rosen, M; Schuchter, L, 2011) |
" This phase I/II study in patients with advanced melanoma evaluated the potential effect of sorafenib on the pharmacokinetics of midazolam, omeprazole, and dextromethorphan, specific substrates of CYP3A4, CYP2C19, and CYP2D6, respectively." | 5.15 | Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. ( Flaherty, KT; Frye, RF; Lathia, C; O'Dwyer, PJ; Redlinger, M; Rosen, M; Schuchter, L, 2011) |
"We pretreated cell lines derived from human melanomas, adenocarcinomas, and lymphomas with the PPIs omeprazole, esomeprazole, or pantoprazole and tested their response to cytotoxic drugs in cell death assays." | 3.72 | Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. ( Arancia, G; Belardelli, F; De Milito, A; Fais, S; Federici, C; Iessi, E; Logozzi, M; Lozupone, F; Luciani, F; Lugini, L; Marra, M; Molinari, A; Montinaro, A; Parmiani, G; Rivoltini, L; Spada, M, 2004) |
"Omeprazole treatment increased the proportion of EndoH sensitive tyrosinase, indicating that tyrosinase maturation was impaired." | 1.42 | Omeprazole, a gastric proton pump inhibitor, inhibits melanogenesis by blocking ATP7A trafficking. ( Ichihashi, M; Karaman-Jurukovska, N; Matsui, MS; Muizzuddin, N; Niki, Y; Petris, MJ; Yarosh, DB, 2015) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Matsui, MS | 1 |
Petris, MJ | 1 |
Niki, Y | 1 |
Karaman-Jurukovska, N | 1 |
Muizzuddin, N | 1 |
Ichihashi, M | 1 |
Yarosh, DB | 1 |
Flaherty, KT | 1 |
Lathia, C | 1 |
Frye, RF | 1 |
Schuchter, L | 1 |
Redlinger, M | 1 |
Rosen, M | 1 |
O'Dwyer, PJ | 1 |
Luciani, F | 1 |
Spada, M | 1 |
De Milito, A | 1 |
Molinari, A | 1 |
Rivoltini, L | 1 |
Montinaro, A | 1 |
Marra, M | 1 |
Lugini, L | 1 |
Logozzi, M | 1 |
Lozupone, F | 1 |
Federici, C | 1 |
Iessi, E | 1 |
Parmiani, G | 1 |
Arancia, G | 1 |
Belardelli, F | 1 |
Fais, S | 1 |
1 trial available for omeprazole and Melanoma
Article | Year |
---|---|
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Topics: Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Cytochrome P-450 Enzyme System; Dextrome | 2011 |
2 other studies available for omeprazole and Melanoma
Article | Year |
---|---|
Omeprazole, a gastric proton pump inhibitor, inhibits melanogenesis by blocking ATP7A trafficking.
Topics: Adenosine Triphosphatases; Animals; Cation Transport Proteins; Cell Line, Tumor; Cells, Cultured; Co | 2015 |
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Animals; Antineoplastic Agents; Benzimidazo | 2004 |